Literature DB >> 35937478

Clinical Features, Neuroimaging, and Levodopa-Responsiveness in Holmes' Tremor: A Video-Based Case-Series with a Review of the Literature.

Anumeha Mishra1, Sanjay Pandey1.   

Abstract

Background: Holmes' tremor (HT) is a low-frequency tremor characterized by a combination of rest, posture, and action components. We are reporting the clinical features, neuroimaging findings, and levodopa responsiveness in 12 patients with HT. Cases: The majority of the patients were male (11/12). Dystonia was observed in 10 patients and the remaining two patients had head tremor, a "forme-fruste" of cervical dystonia. The underlying etiologies were vascular (n = 8), head trauma (n = 2), and tumor resection (n = 2). Neuroimaging showed isolated involvement of the midbrain in four, thalamus in two, and basal ganglia and cerebellum in one patient each. A combination of the lesion (thalamus and cerebellum = 2; cerebellopontine angle = 1, and cortical/subcortical = 1) was present in four patients. Levodopa responsiveness was seen in 75% of patients including one with levodopa-induced dyskinesia. Literature Review: Of 139 patients from 49 studies, levodopa was tried in 123 patients. Improvement with levodopa was seen in 71 patients (57.72%). No improvement with levodopa was observed in 33 patients (26.82%) and details regarding therapeutic response were unavailable in 19 patients (15.44%). Conclusions: Dystonia is an important clinical manifestation of HT. Levodopa responsiveness seen in the majority of the patients is consistent with the hypothesis that nigrostriatal pathway damage is crucial for the pathophysiology of HT.
© 2022 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  dystonia; levodopa; tremor

Year:  2022        PMID: 35937478      PMCID: PMC9346238          DOI: 10.1002/mdc3.13501

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  35 in total

1.  [Clinical features and short-term prognosis of Holmes' tremor].

Authors:  Z Q Liu; Z R Wan; X T Jia; X Z Yang; X X Fang; Z Y Zhang
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2019-03-19

2.  Secondary Cervical Dystonia and Titubatory Head Tremor.

Authors:  Sanjay Pandey; Shruti Jain
Journal:  Mov Disord Clin Pract       Date:  2018-12-13

Review 3.  Dystonia and dopamine: From phenomenology to pathophysiology.

Authors:  Bastien Ribot; Jérome Aupy; Marie Vidailhet; Joachim Mazère; Antonio Pisani; Erwan Bezard; Dominique Guehl; Pierre Burbaud
Journal:  Prog Neurobiol       Date:  2019-08-09       Impact factor: 11.685

4.  Post-Thalamic Stroke Movement Disorders: A Systematic Review.

Authors:  Navnika Gupta; Sanjay Pandey
Journal:  Eur Neurol       Date:  2018-06-05       Impact factor: 1.710

5.  Peduncular 'rubral' tremor and dopaminergic denervation: a PET study.

Authors:  P Remy; A de Recondo; G Defer; C Loc'h; P Amarenco; V Planté-Bordeneuve; M H Dao-Castellana; B Bendriem; C Crouzel; M Clanet
Journal:  Neurology       Date:  1995-03       Impact factor: 9.910

Review 6.  Tremor pathophysiology: lessons from neuroimaging.

Authors:  A M Madelein van der Stouwe; Freek Nieuwhof; Rick C Helmich
Journal:  Curr Opin Neurol       Date:  2020-08       Impact factor: 5.710

7.  A special role of the parvocellular red nucleus in lesion-induced spontaneous tremor in monkeys.

Authors:  C Ohye; T Shibazaki; T Hirai; H Wada; Y Kawashima; M Hirato; M Matsumura
Journal:  Behav Brain Res       Date:  1988 Apr-May       Impact factor: 3.332

8.  Thalamic versus midbrain tremor; two distinct types of Holmes' Tremor: a review of 17 cases.

Authors:  N Nsengiyumva; A Barakat; A Macerollo; R Pullicino; A Bleakley; M Bonello; R J B Ellis; S H Alusi
Journal:  J Neurol       Date:  2021-05-11       Impact factor: 4.849

9.  Is nigrostriatal dopaminergic deficit necessary for Holmes tremor to develop? The DaTSCAN and IBZM SPECT study.

Authors:  Agata Gajos; Sławomir Budrewicz; Magdalena Koszewicz; Małgorzata Bieńkiewicz; Janusz Dąbrowski; Jacek Kuśmierek; Jarosław Sławek; Andrzej Bogucki
Journal:  J Neural Transm (Vienna)       Date:  2017-08-23       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.